These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31168059)

  • 1. Renoprotective effects of voluntary running exercise training on aldosterone-induced renal injury in human L-FABP chromosomal transgenic mice.
    Kosaki K; Sugaya T; Ohata K; Tanabe J; Hoshino S; Inoue K; Kimura K; Maeda S; Shibagaki Y; Kamijo-Ikemori A
    Hypertens Res; 2019 Oct; 42(10):1518-1527. PubMed ID: 31168059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human liver-type fatty acid-binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury.
    Ichikawa D; Kamijo-Ikemori A; Sugaya T; Shibagaki Y; Yasuda T; Hoshino S; Katayama K; Igarashi-Migitaka J; Hirata K; Kimura K
    Am J Physiol Renal Physiol; 2015 Jan; 308(2):F114-21. PubMed ID: 25339700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury.
    Hisamichi M; Kamijo-Ikemori A; Sugaya T; Hoshino S; Kimura K; Shibagaki Y
    Hypertens Res; 2018 Jan; 41(1):8-17. PubMed ID: 28978980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.
    Kanaguchi Y; Suzuki Y; Osaki K; Sugaya T; Horikoshi S; Tomino Y
    Nephrol Dial Transplant; 2011 Nov; 26(11):3465-73. PubMed ID: 21525165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective effect of renal liver-type fatty acid binding protein and angiotensin II type 1a receptor loss in renal injury caused by RAS activation.
    Ichikawa D; Kamijo-Ikemori A; Sugaya T; Shibagaki Y; Yasuda T; Katayama K; Hoshino S; Igarashi-Migitaka J; Hirata K; Kimura K
    Am J Physiol Renal Physiol; 2014 Mar; 306(6):F655-63. PubMed ID: 24431207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion.
    Ichikawa D; Kamijo-Ikemori A; Sugaya T; Ohata K; Hisamichi M; Hoshino S; Kimura K; Shibagaki Y
    Nephrology (Carlton); 2018 Apr; 23(4):308-316. PubMed ID: 28063188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1
    Ohata K; Kamijo-Ikemori A; Sugaya T; Hibi C; Nakamura T; Murase T; Oikawa T; Hoshino S; Katayama K; Asano J; Kimura K; Shibagaki Y
    Eur J Pharmacol; 2017 Nov; 815():88-97. PubMed ID: 28888756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury.
    Tanaka T; Doi K; Maeda-Mamiya R; Negishi K; Portilla D; Sugaya T; Fujita T; Noiri E
    Am J Pathol; 2009 Apr; 174(4):1203-11. PubMed ID: 19264908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury.
    Kamijo-Ikemori A; Sugaya T; Hibi C; Nakamura T; Murase T; Oikawa T; Hoshino S; Hisamichi M; Hirata K; Kimura K; Shibagaki Y
    Am J Physiol Renal Physiol; 2016 Jun; 310(11):F1366-76. PubMed ID: 27029427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury.
    Tanaka T; Noiri E; Yamamoto T; Sugaya T; Negishi K; Maeda R; Nakamura K; Portilla D; Goto M; Fujita T
    Nephron Exp Nephrol; 2008; 108(1):e19-26. PubMed ID: 18182783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage.
    Yokoyama T; Kamijo-Ikemori A; Sugaya T; Hoshino S; Yasuda T; Kimura K
    Am J Pathol; 2009 Jun; 174(6):2096-106. PubMed ID: 19435794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan].
    Kamijo-Ikemori A; Ichikawa D; Matsui K; Yokoyama T; Sugaya T; Kimura K
    Rinsho Byori; 2013 Jul; 61(7):635-40. PubMed ID: 24205707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease.
    Watanabe S; Ichikawa D; Sugaya T; Ohata K; Inoue K; Hoshino S; Kimura K; Shibagaki Y; Kamijo-Ikemori A
    Kidney Blood Press Res; 2018; 43(6):1716-1729. PubMed ID: 30472704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy.
    Zuo N; Suzuki Y; Sugaya T; Osaki K; Kanaguchi Y; Wang L; Tomino Y
    Nephrol Dial Transplant; 2011 Jul; 26(7):2127-37. PubMed ID: 21109611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.
    Hisamichi M; Kamijo-Ikemori A; Sugaya T; Ichikawa D; Natsuki T; Hoshino S; Kimura K; Shibagaki Y
    FASEB J; 2017 Jan; 31(1):72-84. PubMed ID: 27663860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of habitual exercise on urinary liver-type fatty acid-binding protein levels in middle-aged and older adults.
    Kosaki K; Kamijo-Ikemori A; Sugaya T; Tanahashi K; Sawano Y; Akazawa N; Ra SG; Kimura K; Shibagaki Y; Maeda S
    Scand J Med Sci Sports; 2018 Jan; 28(1):152-160. PubMed ID: 28247579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal liver-type fatty acid binding protein attenuates angiotensin II-induced renal injury.
    Ichikawa D; Kamijo-Ikemori A; Sugaya T; Yasuda T; Hoshino S; Igarashi-Migitaka J; Hirata K; Kimura K
    Hypertension; 2012 Oct; 60(4):973-80. PubMed ID: 22926951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity.
    Matsui K; Kamijo-Ikemorif A; Sugaya T; Yasuda T; Kimura K
    Am J Pathol; 2011 Mar; 178(3):1021-32. PubMed ID: 21356355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in urinary markers during the acute phase reflects the degree of chronic tubulointerstitial injury after ischemia-reperfusion renal injury.
    Hisamichi M; Kamijo-Ikemori A; Sugaya T; Ichikawa D; Hoshino S; Hirata K; Kimura K; Shibagaki Y
    Biomarkers; 2017 Feb; 22(1):5-13. PubMed ID: 27028054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury.
    Ohata K; Sugaya T; Nguyen HN; Arai K; Hatanaka Y; Uno K; Tohma M; Uechi T; Sekiguchi K; Oikawa T; Nagabukuro H; Kuniyeda K; Kamijo-Ikemori A; Suzuki-Kemuriyama N; Nakae D; Noiri E; Miyajima K
    Nephrology (Carlton); 2024 Mar; 29(3):117-125. PubMed ID: 37950597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.